SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Phase 3
Completed
- Conditions
- PertussisDiphtheriaTetanusHepatitis BHaemophilus Infections
- Interventions
- Biological: DTaP-HB-PRP~T vaccine + OPVBiological: Tritanrix-HepB/Hib™ + OPV vaccineBiological: Oral Polio Vaccine
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 379
- Registration Number
- NCT00343889
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
Phase 3
Completed
- Conditions
- DiphtheriaPertussisHepatitis BPolio
- Interventions
- Biological: DTaP-IPV//PRP~T combinedBiological: DTaP-IPV-HB-PRP~T vaccineBiological: Hepatitis B vaccine
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 310
- Registration Number
- NCT00315055
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
Phase 4
Completed
- Conditions
- MeaslesRubellaMumpsHepatitis A
- Interventions
- Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps RubellaBiological: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 470
- Registration Number
- NCT00313950
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bDiphtheriaTetanusPertussisHepatitis B
- Interventions
- Biological: Tritanrix-HepB/HibBiological: DTaP-IPV-HB-PRP~T
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2133
- Registration Number
- NCT00313911
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Phase 4
Completed
- Conditions
- PoliomyelitisDiphtheriaTetanusPertussis
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 215
- Registration Number
- NCT00304265
Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly
Phase 2
Completed
- Conditions
- Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1080
- Registration Number
- NCT00296829
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bTetanusPoliomyelitisPertussisDiphtheria
- Interventions
- Biological: DT5aP-IPV-Hib 5-component Pertussis vaccineBiological: Infanrix® -IPV+Hib
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 807
- Registration Number
- NCT00287092
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
Phase 1
Terminated
- Conditions
- SmallpoxHIV Infections
- Interventions
- Biological: MVA Smallpox Vaccine
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2
- Registration Number
- NCT00282581
- Locations
- 🇺🇸
University of Miami AIDS Clinical Research Unit, Miami, Florida, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
Phase 2
Completed
- Conditions
- Meningococcal InfectionMeningitis
- Interventions
- Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 145
- Registration Number
- NCT00269477
Immunogenicity and Safety of Verorab™ in Indian Population
Phase 4
Completed
- Conditions
- Rabies
- Interventions
- Biological: Purified Verocell Rabies Vaccine
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 405
- Registration Number
- NCT00260351
© Copyright 2025. All Rights Reserved by MedPath